Yawen Wang

Yawen Wang


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2020 in Acta Ophthalmologica
Verified
Journal Article
Closed access
PDF file
YHYaguang Hu
Yaguang Hu
TCTianyan Chen
Tianyan Chen
MLMiaomiao Liu
Miaomiao Liu
LZLi Zhang
Li Zhang
FWFang Wang
Fang Wang
LLLi Li
Li Li


25 September 2012 in Clinical and Experimental Medicine
Verified
Journal Article
Closed access
PDF file
QHQunying Han
Qunying Han
NLNa Li
Na Li
Qianqian ZhuQianqian Zhu
Qianqian Zhu
LZLi Zhu
Li Zhu
GZGuoyu Zhang
Guoyu Zhang
CHChunqiu Hao
Chunqiu Hao

14 June 2025 in Journal of Controlled Release
Verified
Journal Article
Open access
XSXue Shi
Xue Shi
XZXiejun Zhao
Xiejun Zhao
YHYinli He
Yinli He
LZLinpei Zhang
Linpei Zhang
XZXinmin Zheng
Xinmin Zheng
XLXiaojiao Li
Xiaojiao Li
Sustained replenishment of cell-surface and exosomal PD-L1 has been believed as the most important factor in the progression of PD-L1 antibody therapy resistance. Given that direct genetic blockade of PD-L1 may lead to unintended consequences and that posttranslational modifications (PTMs) are often used as pharmacological targets of cancer therapy, approaches targeting PD-L1 PTMs show great potential as new therapeutic paradigms. Palmitoylation has emerged as a critical PTM for modulating PD-L1 stability and distribution. In this work, it is found that disruption of palmitoylation by 2-bromopalmitate (2-BP) dual-impaired PD-L1 on the cell surface and exosomes. An amphiphilic TME-responsive micelle was fabricated to efficiently deliver 2-BP and the chemotherapeutic agent cisplatin to tumor milieu. The composite formulation unifying elimination of cell-surface and exosomal PD-L1 with chemotherapy synergistically relieved immunosuppression in the tumor bed and draining lymph node, thereby dramatically restraining growth, postsurgical relapse, and metastasis in melanoma resistant to PD-L1 antibody therapy. Moreover, the formulation elicits potent T cell memory responses for long-term protection against tumor rechallenge. In summary, our study takes advantage of an amphiphilic nanoformula combination of a posttranslational modifier and chemotherapy to target tumors resistant to PD-L1 antibody therapy, and paves a new path for multimodal cancer treatment.

4 November 2022 in Cell Reports Methods
Verified
Journal Article
Open access
YLYanqing Li
Yanqing Li
FZFeng Zhu
Feng Zhu
YLYan Li
Yan Li
SPShunli Pan
Shunli Pan
HWHongliang Wang
Hongliang Wang
BLBING LIU
BING LIU
The gut microbiome is essential for human health. Mouse microbiota models, including gnotobiotic mice, are the most prominent tools to elucidate the functions of gut bacteria. Here, we propose a targeted-bacterium-depleted (TBD) model using lytic bacteriophage to selectively deplete gut bacterium of healthy or otherwise defined mice. These phage-treated animals should have a near-complete spectrum of gut bacteria except for the depleted bacterium. To prove the concept, we employed Escherichia coli-specific phage T7 to repress E. coli in the healthy mice. Our results showed that the E. coli-depleted mice exhibited bravery-like behaviors, correlated to the presence of E. coli rather than the equilibrium among gut bacteria. Thus, we demonstrate that the TBD model is a powerful tool to elucidate the function of a specific bacterial species within a near-intact gut microbiota environment and complements gnotobiotic mice models.

29 August 2025 in Advanced Materials
Verified
Journal Article
Closed access
XZXiejun Zhao
Xiejun Zhao
XQXiangchuan Qin
Xiangchuan Qin
RWRuizhe Wang
Ruizhe Wang
YWYawen Wang
Yawen Wang
YHYinli He
Yinli He
XLXiaojiao Li
Xiaojiao Li